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Abstract
Purpose: We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional
clinical factors such as the International Prognostic Score (IPS) among Hodgkin’s disease (HD) patients.
Methods: Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The
majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a
median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP
(10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic
tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV
(iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to
pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS).
Results: Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute
value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-
treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET
parameters (interim/pre-treatment values) were associated with OS: MTVint/pre (p < 0.01), SUVmeanint/pre (p < 0.05),
SUVmaxint/pre (p = 0.01), and iSUVint/pre (p < 0.01). Absolute value SUVmax from interim-treatment scans was
associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with
PFS: MTVint/pre (p = 0.01), SUVmaxint/pre (p = 0.02) and iSUVint/pre (p = 0.01). IPS was associated with PFS (p < 0.05)
and OS (p < 0.01).
Conclusions: Calculated PET metrics may provide predictive information beyond that of traditional clinical factors
and may identify patients at high risk of treatment failure early for treatment intensification.
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Background
Positron emission tomography [1] imaging using [18F]
fluorodeoxyglucose serves as a valuable functional ima-
ging modality in patients with lymphoma [2-4]. The
ability of PET to distinguish between viable tumor and
necrosis or fibrosis in residual masses provides an
advantage over conventional imaging using computed
tomography [5] or magnetic resonance imaging [6-8].
The high sensitivity and specificity of [18F]FDG-PET
imaging for lymphoma staging has been demonstrated
in previous studies [9-12]. Fused FDG-PET and CT ima-
ging combines functional with anatomic information
about the tumor and is now routinely used in radiation
treatment planning. PET-CT is now strongly recom-
mended by the International Harmonization Project in
Lymphoma for staging and reassessment of FDG-avid,
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potentially curable lymphomas such as Hodgkin’s dis-
ease and diffuse large B-cell lymphoma [13].
In Hodgkin’s disease, long-term disease control is high
and late treatment toxicity and secondary cancers are
emerging as new challenges. It is therefore increasingly
important to develop individualized risk-adapted treat-
ment approaches for this disease. Several recent studies
have demonstrated the role of [18F]FDG-PET in predict-
ing clinical outcome for patients with Hodgkin’s disease.
Advani et al showed that a positive [18F]FDG-PET scan
following completion of Stanford V chemotherapy was
predictive of freedom from progression, even after con-
trolling for bulky disease and International Prognostic
Score (IPS) greater than 2 [14]. The potential clinical
utility of [18F]FDG-PET scan may be extended even
further. Although the optimal timing for evaluating early
response to treatment is yet to be defined, a recent joint
Italian-Danish study has prospectively shown that [18F]
FDG-PET scan following two cycles of AVBD che-
motherapy is superior than IPS in predicting progres-
sion-free survival in patients with Hodgkin’s disease [4].
Evaluation criteria of [18F]FDG-PET scans were quali-
tative in these studies. Variability in interpretation of
PET-CT scans, particularly in cases with faint residual
uptake or “intermediate-positive” scans, limits the broad
clinical utility of this tool. Whether quantitative PET
parameters is a predictive factor for disease progression
in Hodgkin’s disease is not well established. Metabolic
tumor volume (MTV) has been described in a previous
study incorporating patients with Hodgkin’s disease and
non-Hodgkin’s lymphoma to be an independent prog-
nostic factor, but this study had a short follow-up period
of 12.7 months and it did not examine the prognostic
value of interim-treatment PET parameters [15]. We
hypothesize that pre- and interim-treatment quantitative
PET parameters may provide increased predictive
strength beyond traditional clinical factors such as the
International Prognostic Score (IPS).
Methods
Patients
We conducted an IRB approved retrospective review of
the medical records of patients who underwent [18F]
FDG-PET scanning at Stanford Hospital and Clinics
between January 2003 and June 2005 in order to maxi-
mize the length of clinical follow-up. During this study
period, 3, 548 [18F]FDG-PET scans were performed. Of
the patients scanned, we identified 57 adult and pedia-
tric patients who were evaluated for Hodgkin’s disease
at presentation or relapse and had interim-treatment
PET-CT scans (Table 1). It was the general policy to
obtain an interim PET-CT scan, but of 57 patients, we
identified 30 patients with corresponding initial staging
PET-CT scans performed at our institution that had
subsequent clinical follow-up. Patients received che-
motherapy with Stanford V [16], ABVD (1), VAMP [17],
or BEACOPP [18]. Choice of chemotherapy and dura-
tion of treatment varied for patients with early and
advanced disease. Following completion of chemother-
apy, radiation therapy (for a total of 20 Gy, 25.5 Gy, or
36 Gy) was administered to involved sites according to
institutional protocols. Among the patients in this study,
one required treatment intensification to ifosfamide, car-
boplatin, and etoposide (ICE) chemotherapy interim-
treatment. One patient received treatment modification
due to poor venous access and switched from ABVD to
CH1VPP (chlorambucil, vinblastine, procarbazine and
prednisolone) after two cycles. Another patient received
the last 2 cycles of ABVD chemotherapy without bleo-
mycin due to pneumonitis. Date of diagnosis, staging
and interim-treatment PET scans, date of local recur-
rence, date of distant progression, date of last follow-up
or death, and disease status were recorded.
PET Imaging protocol
PET images were acquired on a GE Discovery LS PET-CT
scanner (GE Medical Systems, Milwaukee, WI) as pre-
viously described [19]. In brief, each patient received 12 to
18 mCi of FDG 45 to 60 min before PET/CT imaging.
PET data were acquired using about seven bed positions,
with 3 to 5 min of acquisition time per position. Patients
were injected between 12-18 miCi of FDG based on
patient weight. The amount of FDG injected for individual
patients did not vary significantly provided that their
weights did not change significantly between the scans.
Table 1 Patient Characteristics
Parameter No. of patients (%)
Gender Male 20 (67)
Female 10 (33)
Age Range 9 - 75
Median 19.5
> = 45 yo 3
Stage I A 1 (3)
I B 0
II A 10 (33)
II B 3 (10)
III A 5 (17)
III B 4 (13)
IV A 1 (3)
IV B 6 (20)
Bulky Disease 12 (40)
Extranodal Disease 15 (50)
IPS 0 - 2 21 (70)
> = 3 9 (30)
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Measurement of quantitative PET parameters
Hypermetabolic tumor foci were segmented with a soft-
ware application, RT_Image, as previously described (see
Figure 1 for illustrative example) [19]. In brief, images
were displayed as a maximum intensity projection (MIP)
and then each metabolically active lesion was selected
semi-automatically with reference to the patient’s radiol-
ogy report. Next, RT_Image was used to determine
metabolic tumor volume (MTV), the total volume of all
selected tumors in milliliters, mean standardized uptake
value (SUVmean), maximum SUV (SUVmax) and inte-
grated SUV (iSUV), defined as a product of MTV and
SUVmean [19]. We herein refer to these values as abso-
lute value PET parameters.
Interim-treatment scans were performed at a median of
55 days from the staging PET-CT, corresponding to 2
cycles of Stanford V chemotherapy which was the most
commonly used regimen in this cohort of patients.
Interim-treatment scans were then registered to the cor-
responding pre-treatment scans and the identical regions
interrogated. The ratio of interim- to pre-treatment PET
parameters was calculated, for instance, as follows:
interim-treatment SUVmax/pre-treatment SUVmax. We
herein refer to these values as calculated PET parameters.
Statistical Analysis
Clinical relapse was defined as death, biopsy-proven
recurrence or radiographic findings leading to a change
in management based on clinical judgment. The Cox
proportional hazards model was used for univariate ana-
lysis to assess the effect of patient variables and treat-
ment factors on the end points described above.
Survival graphs were generated by the product limit
method of Kaplan and Meier and log-rank analysis was
utilized for differences between proportions. Analysis
was facilitated using R freeware by the GNU project(5)
and Prism v4.0 by GraphPad [20].
Results
Patient characteristics
Of the 30 patients in this cohort, the majority (53%) had
stage III-IV disease, 67% had an IPS of 2 or greater, and
30% had an IPS of 3 or greater. Patient characteristics,
including patient age, gender, stage, bulky disease, extra-
nodal disease, IPS score, and chemotherapy received, are
summarized in Table 1.
Outcomes
At the time of this analysis, median follow-up of the
study group was 50 months. Six of the 30 patients pro-
gressed clinically (Table 2). We did not observe any
non-cancer deaths (for instance, deaths unrelated to
Hodgkin’s disease or its treatment) as the first event.
The Kaplan-Meier 4-year progression-free survival (PFS)
and overall survival (OS) for the entire cohort was 80%
and 90%, respectively (Figure 2). Follow-up for mortality
was complete for all 30 patients, with 4 dead and 26
alive at the time of analysis. The Kaplan-Meier median
OS has not been reached.
PET metrics
The average MTV for the pre-treatment PET-CT scans
was 344 mL (range 8 - 1496 mL). The average value for
maximum SUV in pre-treatment PET-CT scans was
15.9 (range 5 - 44), for mean SUV 5.3 (range 3 - 10),
and for iSUV 1841.6 (range 24 - 8907). The average
MTV for the interim-treatment PET-CT scans was 44
mL (range 0 - 515 mL). The average value for maximum
SUV in interim-treatment PET-CT scans was 4.0 (range
0 - 19.3), for mean SUV 2.1 (range 0 - 7), and for iSUV
223.5 (range 0 - 2983).
Predictive value
PET parameters from pre-treatment scans did not sig-
nificantly correlate with outcomes (results are summar-
ized in Table 3). Absolute value SUVmax from interim-
Figure 1 Maximum intensity projection view of 18F-
fluorodeoxyglucose-positron emission tomography image with
overlay of segmented metabolic tumor volumes (MTV). This is a
representative pre-treatment PET image (left; MTV = 94 mL, SUVmax
= 8.9, SUVmean = 3.4, and iSUV = 319.8) and interim-treatment PET
image (right; absolute value and calculated MTV = 0 mL, SUVmax =
0, SUVmean = 0, and iSUV = 0).
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treatment scans was significantly associated with OS as
determined by univariate Cox proportional hazards (p <
0.01). Absolute value MTV (p < 0.06), SUVmean (p =
0.07), and iSUV (p = 0.10) from interim-treatment scans
did not reach significance for predicting OS in this ana-
lysis. All four calculated PET parameters (int/pre-treat-
ment values) were associated with OS: MTVmid/pre (p <
0.01), SUVmeanmid/pre (p < 0.05), SUVmaxmid/pre (p =
0.01), and iSUVmid/pre (p < 0.01). Absolute value SUV-
max from interim-treatment scans was significantly
associated with PFS (p = 0.01). Three calculated PET
parameters (int/pre-treatment values) were significantly
associated with PFS: MTVmid/pre (p = 0.01), SUVmaxmid/
pre (p = 0.02) and iSUVmid/pre (p = 0.01). For illustrative
purposes, OS (Figure 3A) is plotted with Kaplan-Meier
analysis for SUVmax using the average SUVmax of 4.0
as the cutoff (see “Conclusion” for further discussion).
The distribution of interim-treatment SUVmax values
are displayed in Figure 3B. IPS was associated with PFS
(p < 0.05) and OS (p < 0.01).
Discussion
In our study, we have demonstrated that the absolute
value SUVmax from interim-treatment scans were
significantly associated with OS and PFS on univariate
analysis. In addition, the calculated PET parameters
from interim-treatment/pre-treatment PET-CT scans,
MTVmid/pre, SUVmaxmid/pre, and iSUVmid/pre, were pre-
dictive for PFS and OS. Calculated SUVmean from
interim-treatment/pre-treatment PET-CT scans is also
predictive of OS. This is consistent with the hypothesis
that the chemosensitivity of the tumor as measured by
PET-CT early during treatment is predictive of clinical
outcome.
These data suggest that absolute value and calculated
PET metrics taken from quantitative analysis of PET
imaging may augment the IPS for predicting PFS or OS.
IPS is utilized for prognostication of patients with
advanced Hodgkin’s disease and not early stage disease.
The development of prognostic and predictive tools for
patients beyond standard clinical staging could be an
important advancement for adaptive treatment
approaches. Relapses in this study occurred only in
patients with advanced stage disease, so we could not
determine if quantitative PET parameters were predic-
tive for early stage disease. For the patients in this
Table 2 Characteristics of patients who have relapsed




Chemo Clinical outcome Survival
17 M III A 0 0 Stanford
V
Progressed at completion of chemo and RT Alive
12 F IV B 6 7 Stanford
V
Progressed at completion of chemo and RT Dead
75 M IV B 141 172 ABVD Dyspnea & fluid overload after cycle 4 of ABVD, h/o orthotopic heart
transplant
Dead
40 M III A 74 33 ABVD Expanding large axillary mass, chemo suspended for surgical excision Dead
56 M IV B 7 9 BEACOPP Died unexpectedly after 2 cycles chemo Dead
26 M III A 0 0 ABVD Evidence of disease recurrence on PET-CT but asymptomatic Alive
Figure 2 Progression-free and overall survival. Progression free
survival (PFS, solid line) and overall survival (OS, dashed line) are
represented. Four-year PFS was 80% and OS was 90%.
Table 3 Summary of Cox proportional hazards analysis of
quantitative PET parameters
Parameter PFS p-value OS p-value
Pre-treatment PET Metrics
SUV max NS NS
SUV mean NS NS
MTV NS NS
Interim PET Metrics
SUVmax 0.01 < 0.01
MTV NS NS
iSUV NS NS
SUV mean NS NS
Calculated PET Metrics
MTVint/pre 0.01 < 0.01
SUVmeanint/pre NS < 0.05
SUVmaxint/pre 0.02 0.01
iSUVint/pre 0.01 < 0.01
NS - not significant.
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study, PFS and OS are 100% for early stage, non-bulky
disease (n = 9). In a larger group of 101 patients with
favorable early stage disease treated with Stanford V
chemotherapy followed by radiation therapy (20 or 30
Gy) according to established protocols at Stanford, FFP
was 94% and OS was 97% [21]. In our study, four-year
PFS for advanced disease (stage III and IV or early stage
bulky disease) is 70% and OS is 85% (n = 21). In a larger
group of 142 patients with advanced disease treated with
Stanford V chemotherapy followed by 36 Gy to involved
sites at Stanford, 5-year PFS was 89% and OS was 96%
[16]. The small sample size in our study limits our abil-
ity to directly compare clinical outcomes between the
patients in our study and the larger group of patients
with Hodgkin’s disease treated at Stanford.
We showed that absolute value interim-treatment
SUVmax was predictive for OS using the average SUV-
max of 4.0 as the threshold value. This threshold level
was chosen for illustrative purposes to demonstrate
that differences in clinical outcomes can be separated
based upon quantitative PET metrics. This analysis
points to the potential utility of a quantitative
approach for cases that may be difficult to assess
following chemotherapy. However, the optimal cut-off
values to be used in Hodgkin’s disease still needs to be
further evaluated in prospective clinical studies. The
optimal technique and threshold values for segmenting
hypermetabolic tumor foci also warrants further
examination.
We describe several quantitative PET parameters that
may be potentially applicable for predicting clinical out-
come in patients with Hodgkin’s disease. In our study,
PET parameters from pre-treatment scans were not sig-
nificant. This may be due to the small sample size of
our study. Alternatively, it may be that the chemosensi-
tivity of the tumor is more important for predicting
clinical outcome than the magnitude of metabolically
active tumor burden at diagnosis. It is interesting to
note that both interim-treatment absolute value and cal-
culated (interim-treatment/pre-treatment) SUVmax
were predictive for overall survival and progression free
survival. We hypothesize that tumor chemosensitivity
may be reflected in interim-treatment PET scan para-
meters. Absolute value interim-treatment MTV has the
advantage of being more directly measured than calcu-
lated MTV, although calculated MTV has the advantage
of reflecting the change in metabolic activity from base-
line. The absolute value PET parameters were used to
determine the calculated PET parameters (for instance,
absolute value interim-treatment SUVmax/pre-treatment
SUVmax). In our dataset, absolute value SUVmax and
calculated SUVmax were highly correlated (Spearman R
= 0.94 and p = 0.0001). It is also notable that 16
patients had interim-treatment SUVmax of 0, and as a
result, calculated SUVmax also shared the same value 0
for 16 of the 30 patients. The best approach for applying
quantitative PET data in the treatment of patients with
Hodgkin’s disease warrants further study in a prospec-
tive manner.
Our results although preliminary, are consistent with
the joint Italian-Danish study showing that [18F]FDG-
PET scan following two cycles of AVBD chemotherapy
predicts progression-free survival in Hodgkin’s disease
patients. The interpretation of the PET-CT scans differs
in our study in that we employ quantitative analysis
rather than qualitative assessment. The establishment of
quantitative methods of assessing PET-CT scans may
aid in the interpretation of scans with minimal residual
uptake or with “intermediate-positive” disease. It also
has the potential for standardizing the interpretation of
scans to reduce the variability in technique among clini-
cal trials and across different institutions. Since a PET-
CT is generally performed to assess the extent of disease
before and during treatment for patients with Hodgkin’s
disease, quantitative analysis would be a practical and
cost-effective strategy for incorporating these data into
clinical practice.
Figure 3 (A) Overall survival (OS) represented by absolute
value interim-treatment SUVmax with cutoff at average
SUVmax = 4.0. (B) Distribution of absolute value interim-treatment
SUVmax values in this study.
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The limitations of our study are the relatively small
number of patients, relatively small number of clinical
events (progression and/or death), and retrospective
method. Due to the small number of patients, we were
not able to select a more homogenous population of
patients receiving identical chemotherapy regimen, e.g.
our stage I-II patients. Due to the low numbers of
events we were also unable to perform a multivariate
analysis to exclude the influence of other clinical and
treatment related prognostic factors as compared to our
quantitative PET metrics. In spite of these limitations,
we present statistically significant data correlating quan-
titative interim-treatment PET metrics with clinical
progression.
In conclusion, quantitative assessment of FDG-PET
status after chemotherapy will likely be helpful for iden-
tifying patients at high risk of treatment failure at an
early time point when treatment intensification could be
considered. The preliminary findings of our study sup-
ports the quantitative interpretation of FDG-PET images
as possibly an important tool guiding the design of pro-
spective clinical trials of functional imaging for Hodg-
kin’s disease.
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